What Researchers Did
Researchers conducted a comprehensive review of the scientific literature to evaluate the role of hyperbaric oxygen (HBO2) therapy for refractory osteomyelitis.
What They Found
The review found that adding hyperbaric oxygen (HBO2) therapy to standard surgical and antibiotic treatment for refractory osteomyelitis appears safe and improves infection resolution rates. Optimal results are typically achieved when HBO2 is given daily (5-7 days/week for 90-120 minutes at 2.0-3.0 atmospheres absolute) with culture-directed antibiotics, ideally soon after surgical debridement. In cases where extensive surgery is contraindicated, a trial of HBO2 and antibiotics offers a reasonable prospect for cure.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor does it involve Canadian authors or specific Canadian patient populations.
Study Limitations
A significant limitation is the absence of randomised clinical trials specifically examining hyperbaric oxygen therapy for refractory osteomyelitis.